华盛顿, 2025年9月9日 - (亚太商讯 via SeaPRwire.com) - 这一公式并不仅仅依赖于中微子，而是基于整个宇宙和地球辐射不可见谱的共振效应。在多层石墨烯—硅结构中，这些辐射通量会激发微观振动，并逐级转化为电子流。这一过程不仅可以通过数学进行计算，也能够在物理上得到验证，如今更已被证明具备工业化规模化的可行性。该方程统一了五个决定性参数：辐射通量密度、散射截面、动量传递、声子速度以及转换效率。它们共同构建了一个严谨的科学框架，将中微子光伏从理论愿景提升为切实可行的现实。全球科学合作致谢中微子能源集团(The Neutrino® Energy Group)谨向无数科学家和科研机构致以最深切的感谢——他们的研究，无论是有意还是无意间，都为我们今天所呈现的成果——中微子光伏技术的主公式——作出了贡献。每一次实验、每一个理论模型、每一项材料创新，都是铺设在道路上的基石。许多奠基者从未料到，他们的研究成果最终会汇聚成一种全新的能源形式。然而，正是通过这张跨越数十年与数大洲的庞大知识网络，这一时刻才得以成为现实。我们向那些在这场全球交响乐中发挥重要作用的顶尖科研机构表达最深切的谢意：马克斯·普朗克学会、弗劳恩霍夫研究所、亥姆霍兹协会、欧洲核子研究中心（CERN）、苏黎世联邦理工学院、巴黎综合理工学院、伦敦帝国理工学院、剑桥大学与牛津大学、中国江门中微子实验（JUNO）、清华大学与北京大学、日本京都大学与大阪大学、东京大学、印度理工学院网络与塔塔基础研究所、印度浦那先进材料电磁研究中心（C-MET Pune）、费米实验室、布鲁克海文国家实验室、麻省理工学院、斯坦福大学、加州大学、美国国家可再生能源实验室（NREL）、巴西圣保罗大学、里约热内卢大学、莫斯科国立大学、俄罗斯杜布纳联合核子研究所（JINR Dubna）、意大利国际理论物理中心（ICTP）、非洲数学科学研究所，以及全球众多纳米技术与材料科学实验室。无论他们专攻的是中微子物理、材料科学、电子学，还是数学，他们的研究都自觉或不自觉地成为这一集体成就的一部分。或许在当时，他们尚未意识到其成果对新时代能源诞生的决定性意义。但今天，我们郑重确认：他们的贡献无价，我们怀着最深的敬意与感激，向他们致以崇高的敬意。主公式在人类历史上首次，一项整合后的方程被公布，它描述了如何将不可见的辐射谱转化为可用电能：P = ∫ Φ(E,θ) · σ(E) · Δp · v_ph · η_conv dE dθ该方程统一了不可见辐射谱的通量密度、散射截面、动量传递、晶格中的声子速度以及石墨烯—硅结构的转换效率。它提供了一个严谨的框架——既可通过数学进行计算，也能在物理上得到验证，并已具备工业化规模应用的可行性。中微子能源集团（Neutrino® Energy Group）首席执行官霍尔格·托尔斯滕·舒巴特（Holger Thorsten Schubart）表示：“这一公式及其所代表的技术并非由某一家公司独自完成，而是全球人类共同努力的结晶。它既是馈赠人类的礼物，也是我们的责任，确保清洁、去中心化并具备基荷能力的能源惠及世界各地的人们。”结束呼吁在未来几十年里，全球能源需求将上升到前所未有的高度。人类不能忽视任何通向经济、清洁且可靠能源的道路。中微子光伏是跨学科合作的产物——物理学、数学、材料科学与工程学紧密交织，形成一种几年前还无人能够想象的普适能源形式。曾经零散的洞见，如今已汇聚成超越国界、学科与世代的能源愿景。它提醒我们，未来不是由当下的限制所决定，而是由我们超越这些限制的勇气所塑造。“我们让能源既经济又可持续。我们务实，但敢于追求不可能。我们相信，只要有足够的创造力，不可能终将成为必然。”关于 Neutrino® Energy GroupNeutrino® Energy Group 是一家国际化运作的科学与技术企业。基于粒子物理学的发现，该集团研发中微子光伏技术，将不可见的辐射谱转化为电能。其研究涵盖理论物理、基于石墨烯与硅的先进材料科学，以及能源转换与储存电子学的开发。愿景：为所有人、在世界各地、世世代代提供清洁、去中心化并具备基荷能力的能源。联系信息Holger Thorsten SchubartCEO and member of the Scientific Advisory Boardoffice@neutrino-energy.com+493020924013来源: Neutrino Energy Group Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月9日 - (亚太商讯 via SeaPRwire.com) - 2025年上半年，中国新能源汽车产销延续增长态势，渗透率持续提升。与此同时，头部车企的竞争差距正迅速拉开，与不少车企仍在亏损边缘挣扎相比，赛力斯（601127.SH）聚焦高端智能电动汽车细分领域，持续夯实产品力和技术力，交出了一份兼顾规模与盈利增长的中期答卷。财报数据显示，2025年上半年，赛力斯实现营业收入624.02亿元；归属于上市公司股东的净利润29.41亿元，同比增长81.03%。同期，赛力斯新能源汽车累计销售172,108辆。一系列数据的背后，是赛力斯对高端智能电动车战略的坚定坚守，以及在产品、技术与品牌上的持续突破。高端智能化引领增长 问界车型稳居销冠赛力斯利润跃升的核心动力，来自于问界系列车型的热销。2025年上半年，问界新M5 Ultra、问界M9 2025款、问界M8相继上市，受到市场广泛认可。截至8月，问界全系累计交付已突破75万辆，其中问界M9累计交付超22万辆，稳居50万元级豪华车市场销量冠军；问界M8上市仅4个月，累计交付即突破7万辆，连续蝉联40万元级别销冠。市场研究机构杰兰路的数据显示，问界品牌在2025年上半年品牌发展信心指数中排名第一，问界M9还以85.2分的高分位列新能源车型净推荐值NPS总榜榜首。支撑这一成绩的，不仅是卓越的产品力，还包括赛力斯在交付与服务体系上的全链条能力。依托魔方技术平台，公司实现了多车型的高效开发与快速迭代；超级工厂则让新车能够在极短时间内实现规模化量产；数智质量体系确保了大规模交付下的稳定质量；而新豪华服务理念则让问界在用户体验上持续加分，形成了良性循环的品牌势能。随着问界M8纯电版于8月25日正式上市，以及新款问界M7已于9月5日正式开启预订，将于9月23日正式上市，新能源汽车产品矩阵将进一步完善，满足豪华车用户的多元需求。可以预见，问界在豪华新能源市场的领先地位还将持续稳固。 技术深耕构建发展护城河 品牌价值持续提升卓越的产品力和交付力，建立在对技术的持续深耕之上。此前，赛力斯相继落地了赛力斯魔方技术平台、赛力斯超级增程、赛力斯超级工厂等一系列技术成果，构筑了坚实的技术护城河。2025年上半年，赛力斯持续加码研发，研发费用达到51.98亿元，同比增长154.9%；研发人员同比增长26.6%，占公司总人数的比例提升至36%。高强度研发持续转化为核心技术成果。今年上海车展期间，赛力斯发布智能安全，首创以场景定义安全，构建了包括「生命保护」「车身防护」「健康呵护」「隐私守护」四大安全领域的智能安全体系，全面覆盖用户的出行安全，成为行业智能安全新标杆。 得益于技术力和产品力的双重提升，赛力斯的品牌价值实现了跨越式增长。2025年《财富》中国500强榜单中，公司位列第169位，较去年跃升235个位次，成为排名跃升幅度最大的公司；在《TopBrand 2025中国品牌500强》中，赛力斯以1755.23亿元的品牌价值排名第92位，跻身汽车行业前十；在全国工商联发布的「2025中国民营企业500强」榜单中，公司升至第59位，居重庆民企首位。良好的发展势头，也让赛力斯获得资本市场的持续看好。近半年来，已有近40家券商机构给予公司「买入」评级，普遍看好其在品牌高端化、新能源技术突破上的潜力。在行业进入深度竞争、洗牌加速的背景下，赛力斯凭借高端智能电动车的精准定位，已在规模、盈利、技术和品牌等多个维度同时实现突破。从短期业绩的持续跃升，到长期技术与品牌价值的沉淀，公司正走出一条高质量发展之路。随着公司持续推动豪华车型，赛力斯销量以及盈利能力有望不断上升。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月9日 - (亚太商讯 via SeaPRwire.com) - 据联想控股微空间报道，为进一步连接资本与科技创新的双赢机会，香港交易所（下称港交所）于9月5日在深圳举办了主题为"智汇创新 共塑未来"的未来科技峰会。在主题对话环节，联想控股董事长宁旻分享了联想的科技创新历程和最新策略、出海国际化的战略思考与经验做法，以及在AI方面的战略布局及最新进展。此外，他还强调了香港资本市场在推动企业创新发展和全球化进程中的关键支持作用。峰会现场，港交所行政总裁陈翊庭致开幕辞。她表示，过去一年不仅见证了中国科技力量的集中爆发，也见证了全球投资热情重回港股市场。未来港交所将继续为市场提供多元化产品、充裕流动性和高效互联的互通机制，服务实体经济和科技创新，继续提升港股之于IPO发行的吸引力和国际竞争力。在之后的一对一主题对话环节中，港交所董事总经理、市场主管余学勤与宁旻展开了深入交流。对于科技创新，宁旻介绍了联想控股在当下的自我定位，是希望发挥在科技领域的综合优势，成为"中国科技成果产业化的引领者"、"中国科技产业生态的参与者、赋能者"。他表示，从创业至今，"科技创新"就一直镌刻在联想基因里。从科技成果转化，到扛起民族计算机产业大旗，再到支持更多的科技创业创新企业发展，公司科技创新的内涵也越来越丰富。宁旻介绍，目前联想控股已形成涵盖四个层次的科技创新体系：- 以联想集团等旗下企业为代表，围绕主业加大研发投入；- 以旗下基金投资公司等为代表，围绕科技前沿展开投资布局。截至目前，联想控股体系每年投资中国科技企业约百家，2024年有13家被投企业上市，位列中国创投行业直投领域榜首。在AI领域，投资了超270家企业，拥有非常完整和全面的AI生态体系；- 联想控股及旗下多家上市公司围绕早期技术，开展商业化研究。目前，联想控股体系内成立了多个研究中心，包括联想控股本部的前瞻技术研究院、联想集团的联想研究院、联泓新科的新材料研究院等。目前与国内几乎全部顶尖高校有合作，特别是与大股东——中国科学院合作，带来一系列科技成果产业化机会和成果，孵化出联泓新科这样的上市公司；- 围绕科技创业坚持公益培训。目前已有超1300名创业者参加了联想之星创业CEO特训班，其中包括185家国家级专精特新企业代表，61家企业上市，形成了中国最大的科技创业生态圈。针对外界所关心的"为广大中国企业持续打造高质量‘出海’典范"的话题，宁旻以联想集团的实践成果为例做了分享。他表示，出海不仅是市场的扩张，更是系统性能力的锻造，联想集团目前正在从三个方面系统提升国际化竞争力：- 以中东为支点升级新的韧性网络；- 以AI+ESG重塑出海竞争力内核。面对国际环境的深刻变化，将技术赋能与可持续发展作为当前高质量出海的两大基座；- 以"中国智造"标准，构建中国企业出海新生态。宁旻强调：联想集团的全球化是根植于中国的全球化，约80%的生产制造、70%的研发人员和60%的员工都布局在中国，通过加速"中国创新-全球应用"循环，正为中国经济注入新的活力。针对AI这一热门话题，宁旻介绍了联想集团"All in AI"的战略布局和联想控股的AI投资版图，"目前，人工智能已经进入到行业的拐点，行业重心从大模型的研发转向了垂直应用，这对于中国企业是非常好的机遇期，联想控股正在以人工智能技术突破为支点，加速推动人工智能与实体经济深度融合。"宁旻介绍，联想集团基于率先提出的混合式AI战略方向，依托业界少有的"端-边-云-网-智"全栈智能技术体系，为客户提供混合式AI解决方案的相关情况。此外，联想控股及旗下基金公司投资超过了270家AI企业，在"基础层-技术层-模型层-平台层-应用层"实现全栈布局，是目前AI投资领域体系最完整、企业数目最多的投资机构，建立起了生态优势。截至目前，联想已与香港资本市场共同走过三十多年合作共赢历程。宁旻表示，港交所近年来围绕科技企业上市推出了一系列改革措施，联想控股始终积极响应，"从2021年算起，联想控股体系共推动22家被投企业登陆港股市场，平均每年约5家被投企业在港股上市，数量在中国一级市场基金当中持续名列前茅。"此外，联想还积极响应港交所有关ESG倡议，是最早开始系统化开展ESG工作并进行信息披露的港股上市公司之一，"经过20年的努力，我们在ESG领域取得了一系列成绩。"宁旻表示，港交所的先进理念和创新政策、独特优势和资源，为科技企业的长期发展奠定了扎实基础，联想控股将继续积极响应港交所新政，持续推动被投科技企业赴港上市，做大做强，走向世界。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Washington, D.C., Sept 9, 2025 - (ACN Newswire via SeaPRwire.com) - The formula does not rely on neutrinos alone, but on the combined resonance of the entire invisible spectrum of cosmic and terrestrial radiation. Within multilayer graphene-silicon structures, these fluxes awaken micro-vibrations that cascade into electron flows. It is a process mathematically calculable, physically verifiable, and now proven industrially scalable.The equation unites five decisive parameters: radiation flux density, scattering cross-section, momentum transfer, phonon velocity, and conversion efficiency. Together, they provide a rigorous scientific framework that elevates neutrinovoltaics from theoretical vision to practical reality.Acknowledgment of Global Scientific CollaborationThe Neutrino® Energy Group expresses its profound gratitude to the countless scientists and institutions whose work, whether knowingly or unknowingly, has contributed to what we present today: the Master Formula of Neutrinovoltaic Technology.Every experiment, every theoretical model, every material innovation has been a stone laid in the path. Many of those who placed these stones could never have foreseen that their findings would converge into an entirely new form of energy. Yet through this vast web of knowledge, scattered across decades and continents, this moment has become possible.We extend our deepest thanks to leading institutions whose voices have shaped this global symphony: Max Planck Society, Fraunhofer Institutes, Helmholtz Association, CERN, ETH Zurich, École Polytechnique, Imperial College London, Cambridge and Oxford, JUNO in China, Tsinghua and Peking Universities, Kyoto and Osaka Universities, University of Tokyo, IIT network and Tata Institute of India, C-MET Pune, Fermilab, Brookhaven, MIT, Stanford, University of California, NREL, University of São Paulo, Rio de Janeiro, Moscow State University, JINR Dubna, ICTP Italy, African Institute for Mathematical Sciences, and many nanotechnology and materials science laboratories worldwide.To each of them-whether they pursued neutrino physics, material science, electronics, or mathematics-their work has knowingly or unknowingly become part of this collective achievement. To many, it may not have been clear at the time how decisive their findings would become for the birth of a new energy age. Today, we affirm that their contribution is invaluable, and we honor it with the deepest respect and gratitude.The Master FormulaFor the first time, a consolidated equation has been published that describes the conversion of invisible radiation spectra into usable electrical energy: P = ∫ Φ(E,θ) · σ(E) · Δp · v_ph · η_conv dE dθThis equation unites the flux density of invisible radiation spectra, the scattering cross-section, the momentum transfer, the phonon velocity in the lattice, and the conversion efficiency of graphene-silicon structures. It provides a rigorous framework, mathematically calculable, physically verifiable, and industrially scalable.Holger Thorsten Schubart, CEO of Neutrino® Energy Group, stated: "This Formula and the technology it represents are not the work of one company, but the culmination of global human effort. It is both a gift to humanity and a responsibility to ensure that the benefits of clean, decentralized, and baseload-capable energy reach people everywhere."Closing AppealThe global demand for energy will rise to unprecedented levels in the decades to come. Humanity cannot afford to ignore any pathway that leads to affordable, clean, and dependable energy. Neutrinovoltaics is the product of interdisciplinary collaboration-physics, mathematics, material science, and engineering woven together into a universal form of energy no one could have imagined only a few years ago.What began as isolated insights has converged into a vision of energy that transcends borders, disciplines, and generations. It is a reminder that the future will be shaped not by the limits of today, but by the courage to move beyond them."We make energy affordable and sustainable. We are realistic, but demand the impossible. We believe that with enough ingenuity the impossible becomes the inevitable."About Neutrino® Energy GroupThe Neutrino® Energy Group is an internationally operating science and technology enterprise. Based on discoveries in particle physics, the Group develops neutrinovoltaic technology, the conversion of invisible radiation spectra into electrical energy. Its work spans theoretical physics, advanced material research with graphene and silicon, and the development of electronics for energy conversion and storage.The vision: clean, decentralized, and baseload-capable energy for all people, in every place, for generations to come.Contact InformationHolger Thorsten SchubartCEO and member of the Scientific Advisory Boardoffice@neutrino-energy.com+493020924013SOURCE: Neutrino Energy Group Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 2, 2025 - (ACN Newswire via SeaPRwire.com) - On August 29, Yuzhou Group Holdings Company Limited (01628.HK) announced that its offshore debt management and restructuring efforts, which spanned over three years, have yielded decisive results. The offshore restructuring has officially taken effect, marking a key step in improving the Company’s liquidity and optimizing its financial structure, laying a solid foundation for future robust operations.Optimize Capital Structure, Enhance Financial Stability and Achieve Sustainable DevelopmentAfter multiple rounds of negotiations, the final arrangement encompassed 15 senior notes, one perpetual bond, four secured notes, one syndicated loan, and one bilateral loan. As consideration for the restructuring, Yuzhou Group issued new bonds with an optimized structure, including short-term, medium-term, and long-term bonds. This arrangement significantly reduced financing costs, lowered the Group’s outstanding offshore debt, alleviated financial pressure, optimized its capital structure, and enhanced financial soundness and sustainability.Gain Support from Shareholders and the Market, Consolidate the Interests of all Parties, and Work Together to Move ForwardAs a key component of the plan, certain creditors will receive 5,645 million newly issued shares, representing approximately 37.94% of Yuzhou Group’s issued shares after the restructuring. This further solidified the shared interests of creditors and the Company. In addition, Yuzhou Group raised nearly HK$100 million through a rights issue to cover restructuring-related expenses and replenish working capital. The arrangement not only set a market precedent but also garnered a positive response from minority shareholders, reflecting strong recognition and confidence from shareholders and the market in both the rationale of the plan and the Group’s future development prospects.The core objective of this restructuring plan was to adjust the scale of Yuzhou Group’s offshore debt to a reasonable level, restore the soundness and sustainability of the capital structure, and ensure the continued operation and healthy development of the business. At the same time, the plan aims to ease liquidity pressure, align the new repayment schedule with the operating environment of China’s real estate industry and the Group, and ensure the fair treatment and protection of all stakeholders’ rights, striving to maximize overall value.Respond to Policy Calls, Fulfill Social Responsibilities, and Consolidate Corporate ValueFollowing the completion of the restructuring, Yuzhou Group will continue to respond to policy initiatives, fulfill its commitment to “guaranteeing housing delivery”, strengthen cash flow management, enhance internal revenue generation capabilities, and ensure stable business operations. Structural deleveraging measures are expected to help the Group achieve a long-term sustainable capital structure and reduce overall operational risks. The Company will steadily enhance its operating capacity and remain focused on creating value for all stakeholders.Industry observers note that the completion of the restructuring not only relieves near-term financial pressure but also represents an important step for Yuzhou Group in pursuing long-term stability and growth amid the ongoing adjustment of China’s real estate sector. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 1, 2025 - (ACN Newswire via SeaPRwire.com) - On August 29, Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company’s total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. Non-IFRS loss narrowed by 31%, and gross margin excluding non-cash items was 76.4%. As of the end of June, the Company maintained a solid cash balance of RMB 1.6 billion. Additionally, with the successful completion of a share placement on August 1, which generated net proceeds of HK$1.553 billion, Everest’s total cash position increased further, providing a strong foundation for commercialization expansion and R&D investment. Supported by the excellent performance of its core products, Everest remains confident in achieving its full-year revenue guidance of RMB 1.6 to 1.8 billion and expects to turn operating cash flow positive in Q4.BOCOM International released its latest report today, noting that the strong sales performance of Everest Medicines’ Nefecon(R) far exceeded expectations. The institution significantly raised its revenue forecasts for 2026–2027 and lifted its target price to HK$84. The report highlighted a rich pipeline of catalysts from the second half of 2025 through 2026, including the approval, commercialization, and reimbursement negotiations of etrasimod in China, as well as potential BD opportunities for the Company’s proprietary pipeline. BOCOM International believes the current valuation remains attractive and reiterated its “Buy” rating.“In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical company by deepening our ‘dual-engine’ strategy. We have built a commercialization platform anchored by two blockbusters covering high-potential markets and powered by the in-house discovery and clinical translation of in vivo CAR-T and mRNA therapeutic cancer vaccine platforms.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.Core Products Deliver Strong Growth, Driving Commercial Platform MomentumNEFECON(R), the blockbuster product in the renal portfolio, delivered particularly strong performance. As the first and only fully approved etiological treatment for IgA nephropathy (IgAN) in China, the United States, and Europe, NEFECON(R) generated revenue of RMB 303 million in the first half of 2025, representing 81% year-over-year growth. However, our first half revenue was artificially low due to a supply constraint that was rooted in both strong market demand and a delay in regulatory approval of a supplemental application for production scale up designed to ensure supply stability. This has been fully resolved since our supplemental application was approved by the China CDE on Aug 1, 2025. Following the supplemental application was approved by the China CDE in August, supply capacity increased significantly. Cumulative sales from January to August reached RMB 825 million, including RMB 520 million in August alone, reflecting strong market demand. Full-year sales are expected to reach RMB 1.2–1.4 billion, with continued strong growth projected in 2026, potentially reaching RMB 2.4–2.6 billion.Another Core product XERAVA(R), As the world’s first fluorocycline antibiotic recorded RMB 143 million in the first half of 2025, up 6% year-over-year. In-hospital sales increased 37% year-over-year, driven by Everest’s core hospital strategy.Additionally, VELSIPITY(R) (etrasimod), a best-in-disease therapy for moderately to severely active ulcerative colitis (UC), is positioned as Everest’s next growth engine, with its NDA in mainland China expected to be approved in the first half of 2026. The localized production project for VELSIPITY(R) was officially launched at the Jiashan manufacturing site in March 2025, providing strong support for its future commercialization.Global Proprietary Pipeline Value Emerging，Strong Prospects for Blockbuster Potential Everest continues to focus on achieving key breakthroughs in its proprietary pipeline, while accelerating the clinical development and global expansion of innovative assets with global rights. EVER001 (civorebrutinib), the next-generation covalent reversible BTK inhibitor, has delivered encouraging Phase 1b/2a clinical data in primary membranous nephropathy (pMN). With potential applications in IgAN, minimal change disease (MCD), and FSGS, covering a patient population of more than 10 million worldwide, EVER001 represents a significant market opportunity, with projected global peak sales exceeding RMB 10 billion. A global Phase II basket trial is expected to be initiated in the first half of 2026.Leveraging its industry-leading mRNA therapeutic cancer vaccine platform and in vivo CAR-T platform, the Company is building a globally competitive R&D pipeline. EVM18, the in vivo CAR-T program, has completed multiple non-human primate (NHP) trials and achieved preclinical proof-of-concept, with first-in-human data expected by the end of 2025. EVM16, the personalized therapeutic mRNA cancer vaccine, has initiated its first-in-human trial in China, with patient dosing completed. In the investigator-initiated trial (IIT), dose escalation in the low- and mid-dose cohorts has been completed, with encouraging preliminary data observed. EVM14, an off-the-shelf tumor-associated antigen (TAA) vaccine, has received IND approval from the U.S. FDA and acceptance from China’s NMPA. The Phase I trial in the U.S. is currently underway, with first patient enrollment expected by September 2025. EVM15, the immune-modulatory cancer vaccine, has completed preclinical proof-of-concept and identified its clinical candidate.Strategic Repositioning to Bolster Global CompetitivenessDuring the reporting period, the Hong Kong Stock Exchange approved the removal of the “B” marker from Everest’s stock short name, reflecting recognition of the Company’s strong R&D pipeline, commercialization capabilities, and overall business fundamentals. In addition to the successful top-up placement, Everest invested approximately US$30.9 million in I-Mab (Nasdaq: IMAB) in August 2025. Following the transaction, Everest increased its ownership in I-Mab to approximately 16.1%, becoming its single largest shareholder, further strengthening its global presence in next-generation immuno-oncology therapies.Analysts noted that Everest’s “dual-engine” strategy is rapidly delivering results. On the one hand, the Company’s powerful commercial platform—anchored by NEFECON(R) and VELSIPITY(R) and supported by XERAVA(R), Cefepime-taniborbactam, EVER001, and other high-potential assets—is expected to generate synergies with total peak sales exceeding RMB 25 billion globally. On the other hand, Everest’s in vivo CAR-T and mRNA therapeutic cancer vaccine platforms provide significant long-term growth potential through global development and partnership opportunities. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com